Drug industry giants managed last year to allay some concerns about drug prices. Pharmacy Benefit Managerswhile publicly agreeing to lower some rates with the White House. These flashy announcements helped create the illusion that action was being taken to help Americans pay less for their prescription drugs, and the pharmaceutical industry received some improvement in its image. CEOs, the faces of these companies, promised to lower prices in front of the general public. It was all great stuff.
But many analysts and other industry experts believe so It didn’t really happenas the prices of many drugs offered on the Trump Rx platform have already been reduced.
Even the prices of GLP-1 drugs, which have actually fallen, have been driven more by market dynamics than by the president’s directive.
And now, a darker side to this effort to unseat President Donald Trump The best nation Drug pricing innovation appears. Companies are now planning to stop launching new drugs in some European countries to avoid setting a reference price that could reduce how much they cost in the U.S. Insmed is delaying the launch of the inflammatory lung disease drug Brunsupri while it is cleared in Europe.
Following Ensmid’s decision to launch a newly approved lung disease drug in Europe, experts predict other companies will follow suit as they seek to avoid price erosion in the U.S. Will Chinese biotechs fill the gap?
According to the latest report, others are re-evaluating their strategies Reuters. “We are seeing the first signs of delayed recognition in Europe,” Stefan Uelreich, Bayer executive and president of the trade group of the Federation of European Pharmaceutical Industries and Associations, told the media.
I spend a lot of time trying to express the human side of this business. People and scientists who create and invent, cure diseases and promote medical advances. They save lives. I hear all the time that working medicine is about patients.
Is it about the patients? Stop promising new drugs from the Europeans so that the Americans will have to pay more?
It doesn’t help anyone. Americans are still paying huge sums of money for new drugs—probably amounts the average person can’t afford—and Europeans aren’t getting it at all.
i get it We have to pay for innovation somehow. The United States is the largest and most profitable market in the world. I don’t have a solution, but I certainly know how to keep important drugs from patients who desperately need them.
Elsewhere, Doctors Without Borders/Médecins Sans Frontières (MSF) launched one Public campaign this week Pressure on Gilead to sell FDA-approved HIV prevention drug Sunlinka. The nonprofit claims that, while they can afford the product, Gilead is refusing to increase production from a $2 million supply that was earmarked for the Global Fund to Fight AIDS, Tuberculosis and Malaria.
Only a handful of top pharmas have signed best-nation drug pricing deals with the White House, while smaller biotechs are still on the hook.
MSF claims that this is not enough, and many countries that need the medicine cannot get it due to restrictions imposed by Gilead.
“Gilead has to decide whether it prioritizes protecting people or protecting control and profits,” said Tom Elman, director of MSF’s South Africa medical unit. “This is a striking echo of the policies we saw in the 1990s when people in the global North were given antiretrovirals while the rest of the world was denied access and many lives were lost to HIV/AIDS.”
In a statement, Gilead did not directly respond to the situation with MSF, but said the company is “committed to ensuring widespread, sustainable access to linacapavir for HIV prevention in high-incidence, resource-limited countries.” Gilead is Working with other organizations and initiatives, including access to the International Monetary Fund and the President’s Emergency Plan for AIDS Relief (PEPFAR). Preventive medicine And generic manufacturers have already been given access to produce copies of it. Let’s hope these parties come together to provide these countries with everything they need to prevent HIV.
Any action that limits a patient’s access to necessary medication is unacceptable. I agree with MSF. This is an exciting moment in pharma history.
#Editorial #Pharma #reluctant #serve #Europe #rid #MFN #drug #prices